Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qualigen Therapeutics ( (QLGN) ) just unveiled an update.
On June 20, 2025, Qualigen Therapeutics appointed Robert B. Lim as the new Chair of the Audit Committee, replacing Graydon Bensler. Mr. Lim, a business forward lawyer based in Vancouver, brings a wealth of experience in corporate commercial law and litigation, and is recognized as an independent director and audit committee financial expert. His appointment is expected to strengthen the company’s governance and oversight capabilities.
Spark’s Take on QLGN Stock
According to Spark, TipRanks’ AI Analyst, QLGN is a Underperform.
Qualigen Therapeutics’ overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.
To see Spark’s full report on QLGN stock, click here.
More about Qualigen Therapeutics
Average Trading Volume: 59,790
Technical Sentiment Signal: Sell
Current Market Cap: $2.67M
For detailed information about QLGN stock, go to TipRanks’ Stock Analysis page.